NCT00252850View on ClinicalTrials.gov

Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Parkinson's Disease
Interventions
GENETIC

CERE-120: AAV2-NTN

Trial Locations (2)

60612

Rush University Medical Center, Chicago

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Ceregene
All Listed Sponsors
collaborator

Ceregene

INDUSTRY

lead

Sangamo Therapeutics

INDUSTRY